Lawsuit Reminder: Faruqi & Faruqi Informs Novo Nordisk Shareholders About the Imminent Class Action Lawsuit with the Lead Plaintiff Deadline Set for September 30, 2025 - NVO
In a significant development, the leading national securities law firm, Faruqi & Faruqi, LLP, is investigating potential claims against Novo Nordisk A/S. The investigation comes in the wake of allegations that the company and its executives may have violated federal securities laws by making false and misleading statements.
The investigation was triggered following a decline in Novo's stock price. On July 29, 2025, the stock price fell to $53.94 per share, a decline of about 21.83% from its closing market price of $69.00 per share on July 28, 2025. This dramatic drop in price followed the news of Novo lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025.
The complaint filed against Novo alleges several misrepresentations. It claims that the company overstated the potential GLP-1 market or its capability to penetrate said markets to achieve continued growth. Furthermore, it alleges that Novo overstated the likelihood of patients switching to Novo's branded alternatives. Additionally, the complaint asserts that Novo understated the potential impact of the personalization exception to the compounded GLP-1 exclusion.
Anyone with information regarding Novo's conduct is encouraged to contact Faruqi & Faruqi, LLP. This includes whistleblowers, former employees, shareholders, and others. The investigation concerns securities purchased or acquired in Novo between May 7, 2025, to July 28, 2025.
If you are a shareholder and wish to participate in the federal securities class action against Novo, you have until September 30, 2025, to seek the role of lead plaintiff. It is important to note that your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice.
For discussions about the investigation, you can contact Josh Wilson, a partner at Faruqi & Faruqi, directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You can also follow Faruqi & Faruqi, LLP for updates on LinkedIn, X, or Facebook. To learn more about the Novo Nordisk class action, visit www.faruqilaw.com/NVO.
It is important to note that this is an ongoing investigation, and more details may emerge as the investigation progresses. Stay tuned for further updates.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Trump's Policies: Tariffs, AI, Surveillance, and Possible Martial Law
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
